查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1992447

癌症影像系统市场：按产品类型、应用、技术和最终用户划分－2026-2032年全球市场预测

Cancer Imaging System Market by Product Type, Application, Technology, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，癌症影像系统市场价值将达到 192.4 亿美元，到 2026 年将成长至 200.7 亿美元，到 2032 年将达到 284.5 亿美元，复合年增长率为 5.74%。

主要市场统计数据
基准年 2025 192.4亿美元
预计年份：2026年 200.7亿美元
预测年份 2032 284.5亿美元
复合年增长率 (%) 5.74%

针对当前癌症影像学面临的关键挑战，制定了一个全面的框架，重点在于诊断准确性、工作流程整合以及临床领导者的策略投资重点。

现代肿瘤学领域对兼具诊断准确性和操作效率的影像系统提出了更高的要求。电脑断层扫描 (CT)、磁振造影(MRI)、混合成像模式以及人工智慧驱动的工作流程的进步，正在改变临床医生检测、分期和后续观察恶性肿瘤的方式。放射科团队和医院管理者如今在评估影像投资时，不仅关注影像质量，还关注互通性、处理能力、病患舒适度以及透过多学科协作对后续治疗路径的影响。

影像技术、电脑辅助增强技术和护理路径整合的进步正在重塑肿瘤影像诊断工作流程和采购策略。

癌症影像领域正经历一场变革，这场变革由三大并行因素驱动：影像技术创新、电脑辅助和诊疗路径整合。影像技术创新不断提升CT和MRI平台的空间和时间分辨率，而混合系统和检测器技术的进步则缩短了扫描时间并提高了病灶的可见度。同时，人工智慧和3D视觉化工具等电脑辅助手段正在提高诊断的一致性，并透过提高病灶检出率、自动化定量测量和标准化机构间报告，加快决策速度。

到 2025 年，我们将重组医疗影像供应商的采购、资金筹措和生命週期规划，评估价格调整带来的采购压力和供应链弹性策略。

2025年新关税措施的实施将加强对医疗影像生态系统供应链的审查力度，促使采购经理重新评估零件来源、製造地和整体拥有成本假设。进口影像零件和资本设备的关税将给采购预算带来上行压力，迫使采购者重新考虑维护策略、延长设备更换週期，并探索其他资金筹措结构以减轻眼前的财务负担。这种财务压力也普遍推动企业考虑在地化生产和供应网络，以降低跨境贸易政策波动带来的风险。

需要详细的细分见解，将产品类型、临床应用、底层技术和最终用户优先顺序连结起来，以帮助选择治疗方式和服务模式设计。

了解细分市场的细微差别对于使产品选择和服务模式与临床和营运目标保持一致至关重要。就产品类型而言，电脑断层扫描 (CT) 产品涵盖范围广泛，从针对高解析度局部影像优化的锥状射束CT，到提高时间解析度的双多切面CT，再到兼顾速度和影像品质的多层螺旋 CT 系统。同时，数位放射线选项包括 CCD（电荷耦合元件）和平板检测器技术，这些技术会影响剂量效率和工作流程整合。磁振造影(MRI) 提供封闭式系统（优先考虑高磁场下的诊断清晰度）、专用于肌肉骨骼成像的肢体 MRI 系统以及提高患者舒适度的开放式 MRI 解决方案。正子断层扫描 (PET) 的差异化体现在 PET-CT 混合系统（整合解剖和代谢数据）和 PET-MRI 混合系统（结合卓越的软组织对比和分子成像）。超音波诊断透过多普勒分析进行血管评估，透过二维影像进行常规评估，透过3D或四维分析支援体积评估和手术指导，从而不断满足各种临床需求。

供应商的打入市场策略受到区域采用率差异、不同的医疗保健系统、法规环境和基础设施优先事项的影响。

区域趋势对整个癌症影像领域的普及曲线、供应商策略和服务交付模式都产生了显着影响。在美洲，需求主要由整合医疗系统和大规模医院网路驱动，这些系统和网路强调互通性、清晰的报销机制和全生命週期服务合约。製造商通常会与当地服务供应商建立策略合作伙伴关係，以确保运作并支援复杂混合系统的部署。欧洲、中东和非洲（EMEA）地区法规环境和采购机制的多样性导致了不同的普及路径。该地区通常呈现出一种平衡：一方面是集中式学术机构推动早期普及，另一方面是分散式实践优先考虑成本效益高的模式和模组化升级。同时，地缘政治因素和基础设施投资的不平衡可能会加速人们对移动和扩充性影像解决方案的兴趣。

透过结合卓越的硬体、软体生态系统以及优先考虑临床检验和营运连续性的服务模式，实现了竞争优势。

产业相关人员正透过整合硬体卓越、软体服务、数据分析和全面维护计划的整合生态系统来实现差异化竞争。成熟的成像设备製造商持续投资于检测器技术、磁铁设计和混合模态工程，同时加速推进人工智慧演算法和视觉化套件的伙伴关係开发和内部研发，以提供超越影像生成的价值。同时，越来越多专注于人工智慧驱动的侦测、工作流程调整和云端原生影像管理的专业技术公司，正给传统供应商带来越来越大的压力，迫使其扩展软体和服务组合。

为供应商和服务提供者制定可操作的策略重点，重点在于模组化平台、检验的人工智慧、灵活的采购和具有弹性的区域服务结构。

产业领导企业可以透过采取多项相互关联的策略，采取果断行动，确保充分利用不断变化的临床需求和政策变化。首先，他们应优先考虑模组化产品架构和软体可升级平台，使客户能够在不完全更换硬体的情况下延长系统寿命并采用新的分析功能。其次，他们应投资于经过临床检验的人工智慧工具和严谨的多中心研究，以证明其在病灶检测、报告一致性和工作流程效率方面能够带来可衡量的改进，从而简化监管核准流程并促进客户接受。

结合相关人员访谈、临床文献综述和技术比较评估的透明混合方法，可以获得有关诊断成像的实用见解。

本研究整合了一手和二手讯息，旨在得出循证见解和实用建议。一手资讯透过临床放射科医师、影像中心主任、采购负责人和医疗设备服务经理的结构化访谈收集，以了解实际操作、影像模式优先顺序和采购限制。这些定性资讯与技术文献、同行评审的临床研究、监管公告和製造商的产品规格进行交叉比对，以确保与最新的临床证据和器械性能声明保持一致。

结论强调了整合的必要性，即使影像能力与临床路径、采购的实用性以及已证实的患者获益相一致。

随着早期检测、精准分期和个人化治疗方案在癌症治疗中变得日益重要，影像系统将继续在多学科肿瘤临床流程中发挥核心作用。先进的影像硬体、混合成像技术和运算分析的融合正在重塑诊断能力和操作预期。专注于互通性、检验的计算工具和灵活服务模式的医疗服务提供者和供应商将更有能力将技术进步转化为可衡量的临床效益。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 癌症影像系统市场：依产品类型划分

  • 电脑断层扫描
    • 锥状射束CT
    • 双源CT
    • 多切面CT
  • 数位X射线成像
    • 电荷耦合几何
    • 平板检测器
  • 磁振造影
    • 闭式磁振造影
    • 四肢磁振造影
    • 开放式磁振造影
  • 正子断层扫描
    • PET-CT
    • PET MRI
  • 超音波
    • 多普勒分析
    • 3D/4D 分析
    • 二维分析

第九章 癌症影像系统市场：依应用领域划分

  • 乳癌
  • 结肠癌
  • 肺癌
  • 摄护腺癌

第十章 癌症影像系统市场：依技术划分

  • 人工智慧
    • 电脑辅助检测
    • 电脑辅助诊断
    • 工作流程管理
  • 造影影像诊断
    • CT造影剂
    • 磁振造影剂
    • 超音波造影
  • 混合成像
    • PET-CT混合
    • PET-MRI混合
    • SPECT-CT混合
  • 3D可视化
    • 最大强度投影
    • 表面渲染
    • 体绘製

第十一章 癌症影像系统市场：依最终用户划分

  • 学术研究机构
  • 诊所
  • 诊断影像中心
  • 医院

第十二章 癌症影像系统市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 癌症影像系统市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 癌症影像系统市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国癌症影像系统市场

第十六章：中国肿瘤影像系统市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agfa-Gevaert NV
  • Agilent Technologies Inc.
  • Analogic Corporation
  • Barco NV
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • Bracco Imaging SpA
  • Canon Medical Systems Corporation
  • Carestream Health Inc.
  • Danaher Corporation
  • Delphinus Medical Technologies Inc.
  • Elekta AB
  • Esaote SpA
  • F. Hoffmann-La Roche Ltd.
  • FUJIFILM Holdings Corporation
  • GE HealthCare Technologies Inc.
  • Hitachi, Ltd.
  • Hologic Inc.
  • IBA Ion Beam Applications SA
  • Illumina Inc.
  • Konica Minolta Inc.
  • Koninklijke Philips NV
  • Lantheus Holdings Inc.
  • Samsung Medison Co., Ltd.
  • Siemens Healthineers AG
Product Code: MRR-3204321AF6C5

The Cancer Imaging System Market was valued at USD 19.24 billion in 2025 and is projected to grow to USD 20.07 billion in 2026, with a CAGR of 5.74%, reaching USD 28.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 19.24 billion
Estimated Year [2026] USD 20.07 billion
Forecast Year [2032] USD 28.45 billion
CAGR (%) 5.74%

Comprehensive framing of current cancer imaging imperatives emphasizing diagnostic precision, workflow integration, and strategic investment priorities for clinical leaders

The contemporary oncology landscape demands imaging systems that combine diagnostic precision with operational efficiency. Advances across computed tomography, magnetic resonance imaging, hybrid modalities, and AI-driven workflows are changing how clinicians detect, stage, and monitor malignancies. Radiology teams and hospital administrators now evaluate imaging investments not solely on image quality but on interoperability, throughput, patient comfort, and downstream impact on multidisciplinary care pathways.

Clinical adoption is being accelerated by tighter integration between imaging modalities and cloud-enabled data management, while value-based care imperatives drive institutions to quantify diagnostic yield and follow-up reductions. At the same time, regulatory scrutiny and reimbursement dynamics influence procurement timelines and capital planning. Therefore, leaders must synthesize technical performance with clinical workflows and fiscal realities when assessing cancer imaging strategies.

This introduction frames the subsequent analysis by focusing on the interplay between modality innovation, technology convergence, and stakeholder requirements. It underscores the necessity for health systems and diagnostic providers to align selection criteria with long-term clinical objectives and operational resilience, and it sets the stage for deeper examination of industry shifts, policy impacts, segmentation insights, and regional dynamics that shape procurement and adoption decisions.

Observing modality advances, computational augmentation, and care pathway integration reshaping diagnostic workflows and procurement philosophies in oncology imaging

The cancer imaging landscape is undergoing transformative shifts driven by three parallel vectors: modality innovation, computational augmentation, and care pathway integration. Modality innovation continues to refine spatial and temporal resolution across CT and MRI platforms while hybrid systems and advances in detector technology reduce scan times and improve lesion conspicuity. Concurrently, computational augmentation through artificial intelligence and three-dimensional visualization tools enhances lesion detection, automates quantitative measurements, and standardizes reporting across sites, thereby improving diagnostic consistency and enabling accelerated decision-making.

Care pathway integration is aligning imaging outputs with multidisciplinary oncology workflows. Radiology reports increasingly feed structured data into tumor boards, surgical planning, and radiation therapy contouring systems. This integration reduces handoff friction and shortens time-to-treatment for complex cases. Additionally, manufacturers and providers are prioritizing patient-centric features such as open-bore MRI designs and faster CT protocols to improve tolerability and throughput, which in turn impacts scheduling efficiency and downstream revenue cycles.

Finally, procurement and service models are shifting toward outcome-oriented contracts and managed equipment services that bundle uptime guarantees, software updates, and AI tool access. These arrangements reflect a broader industry move away from transactional purchasing and toward partnerships that share operational risk and align vendor incentives with clinical outcomes and system efficiency.

Assessment of tariff-driven procurement pressures and supply chain resilience strategies reshaping sourcing, financing, and lifecycle planning across imaging providers in 2025

The introduction of new tariff measures in 2025 has amplified supply chain scrutiny within the medical imaging ecosystem, prompting procurement leaders to evaluate component sourcing, manufacturing footprints, and total cost of ownership assumptions. Tariffs on imported imaging components and capital equipment have placed upward pressure on procurement budgets, encouraging buyers to revisit maintenance strategies, extend equipment refresh cycles, and explore alternative financing structures that mitigate immediate capital strain. This fiscal pressure has also stimulated wider consideration of regional manufacturing and localized supply networks to reduce exposure to cross-border trade policy volatility.

In response, some vendors have accelerated supplier diversification and nearshoring initiatives, relocating critical supply chain nodes closer to major end markets to limit tariff pass-through and shorten lead times. These strategic shifts, however, require substantial lead-time investments and complex qualification of new suppliers to preserve image quality and device safety. Meanwhile, clinical providers have adapted by emphasizing modular upgrades and software-driven performance enhancements that defer full-platform replacement while still delivering incremental clinical benefits.

Regulatory authorities and reimbursement payers have begun assessing whether tariff-induced cost changes necessitate updates to equipment valuation frameworks and procurement guidelines. Hospitals and imaging centers are increasingly negotiating total lifecycle service agreements and consumables bundling to stabilize operational expenses amid pricing uncertainty. As a result, stakeholders are prioritizing resilient procurement strategies, strengthening vendor partnerships, and integrating scenario-based financial planning to preserve access to advanced imaging capabilities while managing near-term cost impacts.

Granular segmentation insights linking product types, clinical applications, enabling technologies, and end user priorities to inform modality selection and service model design

Understanding segmentation nuances is essential for aligning product selection and service models with clinical and operational objectives. When considering product type, computed tomography offerings range from cone beam CT optimized for high-resolution localized imaging to dual source CT that enhances temporal resolution and multi slice CT systems that balance speed and image quality, while digital radiography options include charged coupled device and flat panel detector technologies that affect dose efficiency and workflow integration. Magnetic resonance imaging is available in closed configurations that prioritize high-field diagnostic clarity, extremity MRI systems that deliver focused musculoskeletal imaging, and open MRI solutions that improve patient comfort. Positron emission tomography remains differentiated by PET CT hybrids that merge anatomical and metabolic data and PET MRI hybrids that combine superior soft-tissue contrast with molecular imaging. Ultrasound continues to serve diverse clinical needs through Doppler analysis for vascular assessment, two-dimensional imaging for routine evaluation, and three-dimensional or four-dimensional analyses that support volumetric assessment and procedural guidance.

Applications drive modality prioritization, with specific clinical use cases such as breast cancer screening and diagnostic workup favoring high-resolution mammographic and hybrid solutions, colorectal cancer surveillance requiring cross-sectional imaging and contrast-enhanced techniques, lung cancer pathways depending heavily on low-dose CT protocols and PET-based metabolic characterization, and prostate cancer management leveraging multiparametric MRI and targeted ultrasound interventions. Technology choices further refine value propositions: artificial intelligence supports computer aided detection, computer aided diagnosis, and workflow management that together improve throughput and diagnostic reliability; contrast imaging modalities rely on CT, MRI, and ultrasound agents to enhance lesion delineation and functional assessment; hybrid imaging configurations such as PET CT, PET MRI, and SPECT CT bring complementary diagnostic dimensions; and three-dimensional visualization techniques including maximum intensity projection, surface rendering, and volume rendering facilitate surgical planning and radiotherapy contouring.

End users present distinct procurement and usage patterns. Academic research institutes prioritize extensibility, advanced analytic capabilities, and study-grade data capture. Clinics and diagnostic imaging centers favor throughput, cost-effectiveness, and integrated reporting that streamlines patient throughput. Hospitals require scalable systems that balance acute care demands with outpatient diagnostic volumes and emphasize serviceability and contract support. Recognizing these segmentation layers enables supply-side and clinical leaders to match modality selection and service models to institutional priorities, ensuring investments support diagnostic yield, operational efficiency, and clinical workflow integration.

Regional adoption contrasts and vendor go-to-market adaptations driven by differing healthcare structures, regulatory environments, and infrastructure priorities

Regional dynamics significantly influence adoption curves, vendor strategies, and service delivery models across the cancer imaging landscape. In the Americas, demand is shaped by integrated health systems and large hospital networks that emphasize interoperability, reimbursement clarity, and lifecycle service agreements; manufacturers often pursue strategic partnerships with regional service providers to ensure uptime and to support complex hybrid installations. Europe, the Middle East & Africa features heterogeneous regulatory environments and procurement mechanisms that create varied adoption pathways; this region commonly balances centralized academic centers driving early adoption with decentralized clinics prioritizing cost-effective modalities and modular upgrades, while geopolitical factors and uneven infrastructure investment can accelerate interest in mobile and scalable imaging solutions.

Asia-Pacific continues to exhibit rapid investment in capacity expansion and technology adoption driven by population-scale screening programs and growing cancer care networks, leading to a diverse landscape where high-volume urban centers adopt cutting-edge hybrid and AI-enabled systems while secondary markets prioritize robust, easy-to-service platforms. Vendors respond by tailoring go-to-market approaches and financing models to regional needs, offering managed service options, training programs, and localized support hubs. These regional contrasts influence product development roadmaps and aftermarket strategies, encouraging vendors to design platforms that balance global technical standards with configurable deployment options for distinct regulatory and clinical contexts.

Competitive differentiation through combined hardware excellence, software ecosystems, and service models that prioritize clinical validation and operational continuity

Industry participants are increasingly differentiating through integrated ecosystems that combine hardware excellence with software services, data analytics, and comprehensive maintenance programs. Established imaging manufacturers continue to invest in detector technologies, magnet design, and hybrid modality engineering while also accelerating partnerships and in-house development of AI algorithms and visualization suites to extend value beyond raw image generation. Concurrently, a growing cohort of specialist technology firms focuses on AI-enabled detection, workflow orchestration, and cloud-native image management, pressuring traditional vendors to broaden their software and service portfolios.

Strategic activity includes partnerships for clinical validation, regulatory submissions for AI tools, and the expansion of service footprints to support complex hybrid installations and bundled consumables. Competitive positioning increasingly depends on demonstrating clinical utility through peer-reviewed evidence and cross-site validation studies that show reproducible improvements in diagnostic accuracy and workflow efficiency. Additionally, vendors that offer flexible financing, comprehensive training, and outcome-linked service agreements gain traction among large health systems seeking to align vendor incentives with clinical performance and operational uptime.

Actionable strategic priorities for vendors and providers focusing on modular platforms, validated AI, flexible procurement, and resilient regional service capabilities

Industry leaders can act decisively to capitalize on clinical demand and policy shifts by pursuing several interlocking strategies. First, prioritize modular product architectures and software-upgradeable platforms that allow customers to extend system life and adopt new analytic capabilities without full hardware replacement. Second, invest in clinically validated AI tools and rigorous multi-center studies that demonstrate measurable improvements in lesion detection, reporting consistency, and workflow efficiency, thereby smoothing regulatory pathways and buyer acceptance.

Third, develop flexible procurement options including managed service agreements, subscription licensing, and outcome-linked contracts that align vendor revenue models with customer operational goals. Fourth, strengthen regional service networks and spare-part ecosystems to mitigate tariff and supply chain risk, and consider nearshoring critical component manufacturing where feasible to stabilize lead times and costs. Fifth, design training and implementation programs that embed imaging outputs into multidisciplinary care pathways, ensuring that new capabilities translate into faster clinical decisions and measurable patient benefit. Executing these priorities will require cross-functional coordination among R&D, regulatory affairs, commercial teams, and clinical partners to deliver cohesive product and service propositions that meet the evolving needs of oncologic care providers.

Transparent mixed-methods approach combining stakeholder interviews, clinical literature review, and comparative technology assessments to produce actionable imaging insights

This research synthesized primary and secondary intelligence to produce evidence-based insights and practical recommendations. Primary inputs included structured interviews with clinical radiologists, imaging center directors, procurement officers, and device service managers to capture operational realities, modality priorities, and procurement constraints. These qualitative inputs were triangulated with technical literature, peer-reviewed clinical studies, regulatory communications, and manufacturer product specifications to ensure alignment with current clinical evidence and device performance claims.

Analytical methods combined thematic analysis of stakeholder interviews with comparative technology assessment frameworks that evaluate image quality, throughput, serviceability, and software integration potential. Supply chain and policy impacts were assessed through scenario planning that considered tariff changes, supplier diversification efforts, and regional manufacturing shifts. Throughout, emphasis remained on verifiable clinical and operational outcomes rather than speculative forecasts, and recommendations were calibrated to align with typical procurement cycles and capital planning horizons across hospital systems and diagnostic providers.

Concluding synthesis emphasizing the necessity of aligning imaging capabilities with clinical pathways, procurement pragmatism, and demonstrated patient benefit

As cancer care increasingly prioritizes early detection, precision staging, and personalized treatment planning, imaging systems will remain central to multidisciplinary oncology pathways. The convergence of advanced modality hardware, hybrid imaging techniques, and computational analytics is reshaping diagnostic capabilities and operational expectations. Providers and vendors who focus on interoperability, validated computational tools, and flexible service models will be best positioned to translate technological advances into measurable clinical gains.

Policy and procurement environments will continue to influence adoption patterns, making supply chain resilience and financing flexibility critical considerations for sustained access to advanced imaging. Ultimately, success will hinge on aligning product capabilities with clinical workflows and outcome metrics, thereby ensuring that investments in imaging technology directly support improved patient pathways and system efficiency. Stakeholders should treat imaging strategy as an integral component of broader oncology program development rather than as an isolated capital decision.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Imaging System Market, by Product Type

  • 8.1. Computed Tomography
    • 8.1.1. Cone Beam Computed Tomography
    • 8.1.2. Dual Source Computed Tomography
    • 8.1.3. Multi Slice Computed Tomography
  • 8.2. Digital Radiography
    • 8.2.1. Charged Coupled Device
    • 8.2.2. Flat Panel Detector
  • 8.3. Magnetic Resonance Imaging
    • 8.3.1. Closed Magnetic Resonance Imaging
    • 8.3.2. Extremity Magnetic Resonance Imaging
    • 8.3.3. Open Magnetic Resonance Imaging
  • 8.4. Positron Emission Tomography
    • 8.4.1. PET CT
    • 8.4.2. PET MRI
  • 8.5. Ultrasound
    • 8.5.1. Doppler Analysis
    • 8.5.2. Three D Four D Analysis
    • 8.5.3. Two D Analysis

9. Cancer Imaging System Market, by Application

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Lung Cancer
  • 9.4. Prostate Cancer

10. Cancer Imaging System Market, by Technology

  • 10.1. Artificial Intelligence
    • 10.1.1. Computer Aided Detection
    • 10.1.2. Computer Aided Diagnosis
    • 10.1.3. Workflow Management
  • 10.2. Contrast Imaging
    • 10.2.1. CT Contrast Agents
    • 10.2.2. MRI Contrast Agents
    • 10.2.3. Ultrasound Contrast Agents
  • 10.3. Hybrid Imaging
    • 10.3.1. PET CT Hybrid
    • 10.3.2. PET MRI Hybrid
    • 10.3.3. SPECT CT Hybrid
  • 10.4. Three D Visualization
    • 10.4.1. Max Intensity Projection
    • 10.4.2. Surface Rendering
    • 10.4.3. Volume Rendering

11. Cancer Imaging System Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Clinics
  • 11.3. Diagnostic Imaging Centers
  • 11.4. Hospitals

12. Cancer Imaging System Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cancer Imaging System Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cancer Imaging System Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cancer Imaging System Market

16. China Cancer Imaging System Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agfa-Gevaert N.V.
  • 17.6. Agilent Technologies Inc.
  • 17.7. Analogic Corporation
  • 17.8. Barco NV
  • 17.9. Becton, Dickinson and Company
  • 17.10. Bio-Rad Laboratories Inc.
  • 17.11. Bracco Imaging S.p.A.
  • 17.12. Canon Medical Systems Corporation
  • 17.13. Carestream Health Inc.
  • 17.14. Danaher Corporation
  • 17.15. Delphinus Medical Technologies Inc.
  • 17.16. Elekta AB
  • 17.17. Esaote S.p.A.
  • 17.18. F. Hoffmann-La Roche Ltd.
  • 17.19. FUJIFILM Holdings Corporation
  • 17.20. GE HealthCare Technologies Inc.
  • 17.21. Hitachi, Ltd.
  • 17.22. Hologic Inc.
  • 17.23. IBA Ion Beam Applications SA
  • 17.24. Illumina Inc.
  • 17.25. Konica Minolta Inc.
  • 17.26. Koninklijke Philips N.V.
  • 17.27. Lantheus Holdings Inc.
  • 17.28. Samsung Medison Co., Ltd.
  • 17.29. Siemens Healthineers AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER IMAGING SYSTEM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER IMAGING SYSTEM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CANCER IMAGING SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CANCER IMAGING SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONE BEAM COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONE BEAM COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONE BEAM COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DUAL SOURCE COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DUAL SOURCE COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DUAL SOURCE COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MULTI SLICE COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MULTI SLICE COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MULTI SLICE COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CHARGED COUPLED DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CHARGED COUPLED DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CHARGED COUPLED DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY FLAT PANEL DETECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY FLAT PANEL DETECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY FLAT PANEL DETECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLOSED MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLOSED MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLOSED MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY EXTREMITY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY EXTREMITY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY EXTREMITY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY OPEN MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY OPEN MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY OPEN MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DOPPLER ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DOPPLER ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DOPPLER ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D FOUR D ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D FOUR D ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D FOUR D ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TWO D ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TWO D ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TWO D ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CT CONTRAST AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CT CONTRAST AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CT CONTRAST AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MRI CONTRAST AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MRI CONTRAST AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MRI CONTRAST AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND CONTRAST AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND CONTRAST AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND CONTRAST AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT HYBRID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT HYBRID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT HYBRID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI HYBRID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI HYBRID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI HYBRID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SPECT CT HYBRID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SPECT CT HYBRID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SPECT CT HYBRID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAX INTENSITY PROJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAX INTENSITY PROJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAX INTENSITY PROJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SURFACE RENDERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SURFACE RENDERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SURFACE RENDERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY VOLUME RENDERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY VOLUME RENDERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY VOLUME RENDERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 272. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 273. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 274. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 275. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 276. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 277. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 279. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 280. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 281. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 282. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS CANCER IM